10-Q quarterly report · filed Nov 9, 2026

ABEONA THERAPEUTICS INC. (ABEO) Q3 2026 10-Q Quarterly Report

Short answer

ABEONA THERAPEUTICS INC. (ABEO) filed its Q3 2026 10-Q quarterly report on Nov 9, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $13M with net income of −$5M.

Q3 2026 key financials · XBRL

Revenue
$13M
+18.6% QoQ
Net income
−$5M
+6.8% YoY · +76.2% QoQ
Operating margin
-96.4%
EPS (diluted)
−$0.08
+33.3% YoY · +77.8% QoQ

Source: XBRL data from the ABEONA THERAPEUTICS INC. (ABEO) Q3 2026 10-Q on SEC EDGAR. USD.

ABEONA THERAPEUTICS INC. Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Q3 revenue $13.5M, versus $0 YoY, entirely from ZEVASKYN product sales
  • Q3 operating loss $13.0M vs $24.0M, operating margin -96.3% vs not meaningful
  • ZEVASKYN, sole product line, generated $13.5M revenue and $5.7M cost of sales
  • Cash resources $134.9M at September 30, 2026, operating cash outflow $45.6M through nine months
  • Outlook: cash sufficient through next 12 months, additional funding potentially needed for development and commercialization

Risk Factors

  • Newly added financing risk: November 6 private placement expected to issue 6,400,000 shares and 1,600,043 pre-funded warrants
  • Most material update, commercial risk: ZEVASKYN revenue reached $33.591 million, but manufacturing, 84-hour shelf-life, and treatment-center execution remain critical
  • Regulatory risk: FDA approval of Ultragenyx’s ABO-102 in September 2026 creates royalty eligibility, but payments remain subject to sales-based constraints
  • Operational risk: APT-1011 acquisition adds an EoE development program requiring FDA approval before $30 million milestone eligibility
  • Liquidity risk: cash and equivalents declined to $66.284 million, with $11.111 million debt principal due by December 31, 2027

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other ABEONA THERAPEUTICS INC. quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.